TY - JOUR AU - Vella, S. AU - Schwartlander, B. AU - Sow, S. P. AU - Eholie, S. P. AU - Murphy, R. L. PY - 2012 DA - 2012// TI - The history of antiretroviral therapy and of its implementation in resource-limited areas of the world JO - AIDS VL - 26 UR - https://doi.org/10.1097/QAD.0b013e32835521a3 DO - 10.1097/QAD.0b013e32835521a3 ID - Vella2012 ER - TY - STD TI - Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2015 Available: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 22 Sept 2016. UR - http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf ID - ref2 ER - TY - STD TI - European AIDS Clinical Society (2014) Guidelines: Clinical management of treatment of HIV infected adults in Europe. 2014 version 7.1. Available: http://www.eacsociety.org/files/guidelines_english_71_141204.pdf. Accessed 22 Sept 2016. UR - http://www.eacsociety.org/files/guidelines_english_71_141204.pdf ID - ref3 ER - TY - JOUR AU - Salter, M. L. AU - Lau, B. AU - Go, V. F. AU - Mehta, S. H. AU - Kirk, G. D. PY - 2011 DA - 2011// TI - HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users JO - Clin Infect Dis VL - 53 UR - https://doi.org/10.1093/cid/cir673 DO - 10.1093/cid/cir673 ID - Salter2011 ER - TY - JOUR AU - Angelantonio, E. AU - Chowdhury, R. AU - Sarwar, N. AU - Aspelund, T. AU - Danesh, J. AU - Gudnason, V. PY - 2010 DA - 2010// TI - Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study JO - BMJ VL - 341 UR - https://doi.org/10.1136/bmj.c4986 DO - 10.1136/bmj.c4986 ID - Angelantonio2010 ER - TY - JOUR AU - Sabin, C. A. AU - Worm, S. W. AU - Weber, R. AU - Reiss, P. AU - El-Sadr, W. AU - Dabis, F. PY - 2008 DA - 2008// TI - Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration JO - Lancet VL - 371 UR - https://doi.org/10.1016/S0140-6736(08)60423-7 DO - 10.1016/S0140-6736(08)60423-7 ID - Sabin2008 ER - TY - JOUR AU - Choi, A. I. AU - Li, Y. AU - Deeks, S. G. PY - 2010 DA - 2010// TI - Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons JO - Circulation VL - 121 UR - https://doi.org/10.1161/CIRCULATIONAHA.109.898585 DO - 10.1161/CIRCULATIONAHA.109.898585 ID - Choi2010 ER - TY - JOUR AU - Mocroft, A. AU - Kirk, O. AU - Reiss, P. PY - 2010 DA - 2010// TI - Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV positive patients JO - AIDS VL - 24 UR - https://doi.org/10.1097/QAD.0b013e328339fe53 DO - 10.1097/QAD.0b013e328339fe53 ID - Mocroft2010 ER - TY - JOUR AU - Bedimo, R. AU - Maalouf, N. M. AU - Zhang, S. PY - 2012 DA - 2012// TI - Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents JO - AIDS VL - 26 UR - https://doi.org/10.1097/QAD.0b013e32835192ae DO - 10.1097/QAD.0b013e32835192ae ID - Bedimo2012 ER - TY - JOUR AU - Choi, A. I. AU - Vittinghoff, E. AU - Deeks, S. G. PY - 2011 DA - 2011// TI - Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons JO - AIDS VL - 25 UR - https://doi.org/10.1097/QAD.0b013e328347fa16 DO - 10.1097/QAD.0b013e328347fa16 ID - Choi2011 ER - TY - JOUR AU - Bavinger, C. AU - Bendavid, E. AU - Niehaus, K. PY - 2013 DA - 2013// TI - Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0059551 DO - 10.1371/journal.pone.0059551 ID - Bavinger2013 ER - TY - JOUR AU - Ofotokun, I. AU - Sheth, A. N. AU - Sanford, S. E. PY - 2012 DA - 2012// TI - A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study JO - AIDS Res Hum Retroviruses VL - 28 UR - https://doi.org/10.1089/aid.2011.0336 DO - 10.1089/aid.2011.0336 ID - Ofotokun2012 ER - TY - JOUR AU - Nishijima, T. AU - Gatanaga, H. AU - Shimbo, T. PY - 2013 DA - 2013// TI - Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0073639 DO - 10.1371/journal.pone.0073639 ID - Nishijima2013 ER - TY - STD TI - Arribas JR, Girard P-M, Landman R. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir– ritonavir plus lamivudine or emtricitabine and a second nucleos(t) ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015. Available at: http://dx.doi.org/10.1016/S1473-3099(15)70129-5. Accessed 1 Oct 2016 ID - ref14 ER - TY - JOUR AU - Giambenedetto, S. AU - Fabbiani, M. AU - Colafigli, M. PY - 2013 DA - 2013// TI - Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for Treatment Simplification, ATLAS pilot study) JO - J Antimicrob Chemother VL - 68 UR - https://doi.org/10.1093/jac/dkt007 DO - 10.1093/jac/dkt007 ID - Giambenedetto2013 ER - TY - JOUR AU - Perez-Molina, J. AU - Rubio, R. AU - Rivero, A. PY - 2015 DA - 2015// TI - Dual treatment with atazanavir ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomized, open label, non inferiority trial JO - Lancet Infect Dis VL - 15 UR - https://doi.org/10.1016/S1473-3099(15)00097-3 DO - 10.1016/S1473-3099(15)00097-3 ID - Perez-Molina2015 ER - TY - JOUR AU - Maggiolo, F. AU - Filippo, E. AU - Valenti, D. AU - Ortega, P. S. AU - Callegaro, A. PY - 2016 DA - 2016// TI - NRTI sparing therapy in virologically controlled HIV-1 infected subjects: results of a controlled randomized trial (Probe) JO - JAIDS VL - 72 ID - Maggiolo2016 ER - TY - STD TI - Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1. 22 novembre 2016. Available at http://www.salute.gov.it/imgs/C_17_pubblicazioni_2545_allegato.pdf. Accessed Jan 2017. UR - http://www.salute.gov.it/imgs/C_17_pubblicazioni_2545_allegato.pdf ID - ref18 ER - TY - JOUR AU - Carr, A. AU - Samaras, K. AU - Burton, S. PY - 1998 DA - 1998// TI - A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors JO - AIDS VL - 12 UR - https://doi.org/10.1097/00002030-199807000-00003 DO - 10.1097/00002030-199807000-00003 ID - Carr1998 ER - TY - JOUR AU - Mulligan, K. AU - Grunfeld, C. AU - Tai, V. W. PY - 2000 DA - 2000// TI - Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV-1 infection JO - JAIDS VL - 23 ID - Mulligan2000 ER - TY - JOUR AU - Cote, H. C. AU - Brumme, Z. L. AU - Craib, K. J. PY - 2002 DA - 2002// TI - Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients JO - N Engl J Med VL - 346 UR - https://doi.org/10.1056/NEJMoa012035 DO - 10.1056/NEJMoa012035 ID - Cote2002 ER - TY - JOUR AU - Jones, R. AU - Sawleshwarkar, S. AU - Michailidis, C. PY - 2005 DA - 2005// TI - Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase backbone JO - HIV Med VL - 6 UR - https://doi.org/10.1111/j.1468-1293.2005.00325.x DO - 10.1111/j.1468-1293.2005.00325.x ID - Jones2005 ER - TY - JOUR AU - Cohen, C. AU - Green, J. AU - Olivet, H. PY - 2012 DA - 2012// TI - A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted atazanavir (ATV/r) vs. raltegravir (RALBID) + ATV/r vs. RAL BID + ATV BID JO - J Int AIDS Soc VL - 15 ID - Cohen2012 ER - TY - JOUR AU - Negredo, E. AU - Molto, J. AU - Burger, D. PY - 2005 DA - 2005// TI - Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study) JO - JAIDS VL - 38 ID - Negredo2005 ER - TY - JOUR AU - Gagliardini, R. AU - Rossetti, B. AU - Bianco, C. PY - 2014 DA - 2014// TI - Safety and therapeutic efficacy of the switch to maraviroc + darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study JO - J Int AIDS Soc VL - 17 UR - https://doi.org/10.7448/IAS.17.4.19818 DO - 10.7448/IAS.17.4.19818 ID - Gagliardini2014 ER - TY - JOUR AU - Lennox, J. L. AU - Landovitz, R. J. AU - Ribaudo, H. J. PY - 2014 DA - 2014// TI - Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial JO - Ann Intern Med VL - 161 UR - https://doi.org/10.7326/M14-1084 DO - 10.7326/M14-1084 ID - Lennox2014 ER - TY - JOUR AU - Clotet, B. AU - Feinberg, J. AU - Lunzen, J. PY - 2014 DA - 2014// TI - Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study JO - Lancet VL - 383 UR - https://doi.org/10.1016/S0140-6736(14)60084-2 DO - 10.1016/S0140-6736(14)60084-2 ID - Clotet2014 ER - TY - JOUR AU - Rockstroh, J. K. AU - DeJesus, E. AU - Lennox, J. L. PY - 2013 DA - 2013// TI - Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK JO - JAIDS VL - 63 ID - Rockstroh2013 ER - TY - JOUR AU - Walmsley, S. AU - Antela, A. AU - Clumeck, N. PY - 2013 DA - 2013// TI - on behalf of the SINGLE investigators. Dolutegravir plus abacavir/lamivudine for the initial treatment of HIV-1 infection JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1215541 DO - 10.1056/NEJMoa1215541 ID - Walmsley2013 ER - TY - JOUR AU - Greig, S. L. AU - Deeks, E. D. PY - 2015 DA - 2015// TI - Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection JO - Drugs VL - 75 UR - https://doi.org/10.1007/s40265-015-0361-6 DO - 10.1007/s40265-015-0361-6 ID - Greig2015 ER - TY - JOUR AU - Wainberg, M. A. AU - Han, Y. -. S. PY - 2015 DA - 2015// TI - Will drug resistance against dolutegravir in initial therapy ever occur? JO - Front Pharmacol VL - 6 UR - https://doi.org/10.3389/fphar.2015.00090 DO - 10.3389/fphar.2015.00090 ID - Wainberg2015 ER - TY - JOUR AU - Castagna, A. AU - Maggiolo, F. AU - Penco, G. PY - 2014 DA - 2014// TI - Dolutegravir in antiretroviral experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study JO - J Infect Dis VL - 210 UR - https://doi.org/10.1093/infdis/jiu051 DO - 10.1093/infdis/jiu051 ID - Castagna2014 ER - TY - JOUR AU - Rojas, J. AU - Blanco, J. L. AU - Marcos, M. A. PY - 2016 DA - 2016// TI - Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression JO - J Antimicrob Chemother VL - 71 UR - https://doi.org/10.1093/jac/dkw078 DO - 10.1093/jac/dkw078 ID - Rojas2016 ER - TY - JOUR AU - Katlama, C. AU - Soulié, C. AU - Caby, F. PY - 2016 DA - 2016// TI - Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia JO - J Antimicrob Chemother VL - 71 UR - https://doi.org/10.1093/jac/dkw186 DO - 10.1093/jac/dkw186 ID - Katlama2016 ER - TY - STD TI - Oldenbuettel C, Wolf E, Ritter A, et al. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Antiviral therapy 2016; doi: 10.3851/IMP3082 ID - ref35 ER - TY - JOUR AU - Gubavu, C. AU - Prazuck, T. AU - Niang, M. PY - 2016 DA - 2016// TI - Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients JO - J Antimicrob Chemother VL - 71 UR - https://doi.org/10.1093/jac/dkv430 DO - 10.1093/jac/dkv430 ID - Gubavu2016 ER - TY - JOUR AU - Capetti, A. F. AU - Sterrantino, G. AU - Cossu, M. V. PY - 2016 DA - 2016// TI - Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort JO - PLoS ONE VL - 11 UR - https://doi.org/10.1371/journal.pone.0164753 DO - 10.1371/journal.pone.0164753 ID - Capetti2016 ER - TY - STD TI - Reynes J, Meftah N, Montes B. Dual therapy with dolutegravir and lamivudine maintains virologic suppression in HIV-infected HAART-treated patients: DOLULAM pilot study. Fifteenth European AIDS Conference, Barcelona, 2015. Abstract PE8/81. ID - ref38 ER - TY - STD TI - Borghetti A, Baldin G, Ciccullo A, et al. Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy. J Antimicrob Chemother 2016; doi:10.1093/jac/dkw147 ID - ref39 ER - TY - STD TI - Figueroa MI, Sued O, Patterson P et al. Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial. Fifteenth European AIDS Conference, Barcelona, 2015. Abstract LBPS4/1. ID - ref40 ER - TY - STD TI - Sued OG, Figueroa MI, Rolon MJ, et al. Comparable Viral Decay in Dual and Triple Dolutegravir-Based Antiretroviral Therapy. Conference on Retroviruses and Opportunistic Infections, Boston 2016. Abstract 947. ID - ref41 ER - TY - JOUR AU - Maggiolo, F. AU - Roat, E. AU - Pinti, M. PY - 2010 DA - 2010// TI - Mitochondrial changes during d-drug-containing once-daily therapy in HIV-positive treatment-naive patients JO - Antivir Ther VL - 15 UR - https://doi.org/10.3851/IMP1483 DO - 10.3851/IMP1483 ID - Maggiolo2010 ER - TY - STD TI - De Boer M, Van den Berk G, Van Holten N, Oryszczyn J, Dorama W, Moha DA, et al. Intolerance of dolutegravir containing cART regimens in real life clinical practice. AIDS 2016; doi: 10.1097/QAD.0000000000001279 ID - ref43 ER - TY - STD TI - Shah BM, Schafer JJ, DeSimone, JA Jr. Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIV. Pharmacotherapy 2013; doi: 10.1002/phar.1386 ID - ref44 ER - TY - STD TI - Post FA, Tebas P, Clarke A, et al. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single Arm, Multicenter, Open-Label Phase 3 Study. JAIDS 2016; doi: 10.1097/QAI.0000000000001186 ID - ref45 ER -